Merck Serono Receives European Approval For Broader Usage Of Erbitux In Metastatic Co
Merck KGaA announced today that it has been granted approval by the European Commission for Erbitux® (cetuximab), to update its license for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type mCRC (metastatic colorectal cancer) in combination with che
Merck Serono Receives European Approval For Broader Usage Of Erbitux In Metastatic Co 
Linear Mode
